Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication

The NS5B RNA-dependent RNA polymerase is an attractive target for the development of novel and selective inhibitors of hepatitis C virus replication. To identify novel structural hits as anti-HCV agents, we performed structure-based virtual screening of our in-house library followed by rational drug design, organic synthesis, and biological testing. These studies led to the identification of pyrazolobenzothiazine scaffold as a suitable template for obtaining novel anti-HCV agents targeting the NS5B polymerase. The best compound of this series was the <i>meta</i>-fluoro-<i>N</i>-1-phenyl pyrazolobenzothiazine derivative <b>4a</b>, which exhibited an EC₅₀ = 3.6 μM, EC₉₀ = 25.6 μM, and CC₅₀ > 180 μM in the Huh 9–13 replicon system, thus providing a good starting point for further hit evolution